专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

71. 发明申请

WO2007025094A2 STABILIZED AND PRESERVED KETOTIFEN OPHTHALMIC COMPOSITIONS 审中-公开
标题翻译：稳定和保存的KETOTIFEN OPHTHALMIC组合物
公开(公告)号：WO2007025094A2
公开(公告)日：2007-03-01
申请号：PCT/US2006/033163
申请日：2006-08-24
申请人： NOVARTIS AG , NOVARTIS PHARMA GmbH , TSAO, Fu-Pao
发明人： TSAO, Fu-Pao
IPC分类号： A61K9/00 , A61K31/4535
CPC分类号： A61K47/38 , A61K9/0048 , A61K31/4535 , A61K47/08 , A61K47/24
摘要： Ophthalmic compositions comprising ketotifen, a source of hydrogen peroxide providing an amount of hydrogen peroxide of from about 0.001 to about 0.1 % (w/v), one or more ocular-compatible hydrogen peroxide stabilizers, HPMC and CMC, and methods for the treatment and prevention of allergic conjunctivitis using these ophthalmic compositions are provided herein.
摘要翻译：包含酮替芬，提供约0.001至约0.1％（w / v）的过氧化氢量的过氧化氢源，一种或多种眼睛相容的过氧化氢稳定剂，HPMC和CMC的眼科组合物，以及用于治疗和本文提供使用这些眼用组合物预防过敏性结膜炎。

72. 发明申请

WO2007025092A2 STABILIZED AND PRESERVED KETOTIFEN OPHTHALMIC COMPOSITIONS 审中-公开
标题翻译：稳定和保存起效的眼用组合物
公开(公告)号：WO2007025092A2
公开(公告)日：2007-03-01
申请号：PCT/US2006/033161
申请日：2006-08-24
申请人： NOVARTIS AG , NOVARTIS PHARMA GMBH , TSAO, Fu-Pao , WONG, Michelle, P. , YEN, Shau, Fong
发明人： TSAO, Fu-Pao , WONG, Michelle, P. , YEN, Shau, Fong
IPC分类号： A61K9/08 , A61K31/4535
CPC分类号： A61K31/4535 , A61K9/0048
摘要： Ophthalmic compositions comprising ketotifen and a source of hydrogen peroxide providing an amount of hydrogen peroxide of from about 0.001 to about 0.1% (w/v) of hydrogen peroxide, and methods for the treatment and prevention of allergic conjunctivitis using these compositions are provided herein.
摘要翻译：包含酮替芬和过氧化氢源的眼用组合物，提供过氧化氢的量为约0.001至约0.1％（w / v）的过氧化氢，以及用于治疗和预防过敏的方法本文提供了使用这些组合物的结膜炎。

73. 发明申请

WO2006136392A3 NOVEL GENES AND PROTEINS OF BRACHYSPIRA PILOSICOLI AND USE OF SAME FOR DIAGNOSIS AND THERAPY 审中-公开
标题翻译： BRACHYSPIRA PILOSICOLI的新型基因和蛋白质及其用于诊断和治疗的用途
公开(公告)号：WO2006136392A3
公开(公告)日：2007-03-01
申请号：PCT/EP2006005961
申请日：2006-06-21
申请人： NOVARTIS AG , NOVARTIS PHARMA GMBH , UNIV MURDOCH , BELLGARD MATTHEW , HAMPSON DAVID JOHN , LA TOM
发明人： BELLGARD MATTHEW , HAMPSON DAVID JOHN , LA TOM
IPC分类号： C12N15/31 , A61K39/02 , C07K14/20 , C07K16/12 , C12N15/85 , C12Q1/68 , G01N33/53
CPC分类号： C07K14/20 , A61K39/00 , A61K2039/53
摘要： Novel polynucleotide and amino acids of Brachyspira pilosicoli are described. These sequences are useful for diagnosis of B. pilosicoli disease in animals and as a therapeutic treatment or prophylactic treatment of B. pilosicoli disease in animals. These sequences may also be useful for diagnostic and therapeutic and/or prophylactic treatment of diseases in animals caused by other Brachyspira species, including B. intermedia, B. alvinipulli, B. aalborgi, B. innocens, B. murdochii, and B. hyodysenteriae.
摘要翻译：描述了Brachyspira pilosicoli的新型多核苷酸和氨基酸。这些序列可用于诊断动物中的布氏梭菌病，并且用作动物中的弓形虫病的治疗性或预防性治疗。这些序列也可用于诊断和治疗和/或预防性处理由其他布氏梭菌属物种引起的动物疾病，包括中间球虫（B.intermedia），乙型肝炎球菌（B.alvinipulli），鲍氏杆菌（B.Aalborgi），无性系B（B.Antocens），黑曲霉（B. murdochii）和猪痢疾梭菌。

74. 发明申请

WO2007022113A2 SOLID DOSAGE FORMS OF VALSARTAN AND AMLODIPINE AND METHOD OF MAKING THE SAME 审中-公开
标题翻译： VALSARTAN和AMLODIPINE的固体剂型及其制备方法
公开(公告)号：WO2007022113A2
公开(公告)日：2007-02-22
申请号：PCT/US2006031699
申请日：2006-08-15
申请人： NOVARTIS AG , NOVARTIS PHARMA GMBH , JOSHI YATINDRA , WAGNER ROBERT FRANK , PUDIPEDDI MADHUSUDHAN , SUNKARA GANGADHAR , LI PING
发明人： JOSHI YATINDRA , WAGNER ROBERT FRANK , PUDIPEDDI MADHUSUDHAN , SUNKARA GANGADHAR , LI PING
CPC分类号： A61K9/209 , A61K9/2027 , A61K9/2054 , A61K9/2095 , A61K31/41 , A61K31/4422 , A61K45/06
摘要： Monolayer and bilayer solid dosage forms of a combination of valsartan and amlodipine are made.
摘要翻译：制备缬沙坦和氨氯地平组合的单层和双层固体剂型。

75. 发明申请

WO2007021666A2 LIQUID FORMULATIONS 审中-公开
标题翻译：液体配方
公开(公告)号：WO2007021666A2
公开(公告)日：2007-02-22
申请号：PCT/US2006/030836
申请日：2006-08-08
申请人： NOVARTIS AG , NOVARTIS PHARMA GmbH , GEORGOUSIS, Vivian , TONG, Wei-Qin
发明人： GEORGOUSIS, Vivian , TONG, Wei-Qin
CPC分类号： A61K47/10 , A61K9/0053 , A61K9/0095 , A61K31/00 , A61K31/137 , C07C215/28 , C07D205/04 , C07F9/141
摘要： Disclosed is a concentrate for dilution comprising a S1P receptor agonist or a pharmaceutically acceptable salt thereof, propylene glycol and optionally glycerin. This formulation is adapted for patients in a difficult condition to swallow.
摘要翻译：公开了一种用于稀释的浓缩物，其包含S1P受体激动剂或其药学上可接受的盐，丙二醇和任选的甘油。该制剂适用于困难条件下吞咽的患者。

76. 发明申请

WO2007019255A2 NEW COMPOUNDS 审中-公开
标题翻译：新化合物
公开(公告)号：WO2007019255A2
公开(公告)日：2007-02-15
申请号：PCT/US2006/030335
申请日：2006-08-02
申请人： NOVARTIS AG , NOVARTIS PHARMA GmbH , REBER, Jean-Louis , VILLHAUER, Edwin, Bernard
发明人： REBER, Jean-Louis , VILLHAUER, Edwin, Bernard
IPC分类号： C07D207/16 , A61K31/401 , A61P3/10
CPC分类号： C07D207/16
摘要： The present invention relates to novel salt forms of vildagliptin (LAF237), i.e. salt forms of (S)-1-[(3-hydroxy-1-adamantyl)amino]acetyl-2-cyano-pyrrolidine.
摘要翻译：本发明涉及维格列汀（LAF237）的新型盐形式，即（S）-1 - [（3-羟基-1-金刚烷基）氨基]乙酰基-2-氰基 - 吡咯烷的盐形式。

77. 发明申请

WO2007016532A2 MUTATIONS AND POLYMORPHISMS OF HDAC4 审中-公开
标题翻译： HDAC4的突变和多态性
公开(公告)号：WO2007016532A2
公开(公告)日：2007-02-08
申请号：PCT/US2006029851
申请日：2006-07-31
申请人： NOVARTIS AG , NOVARTIS PHARMA GMBH , CULVER KENNETH WAYNE , ZHU JIAN , LILLEBERG STAN
发明人： CULVER KENNETH WAYNE , ZHU JIAN , LILLEBERG STAN
IPC分类号： A61K31/00
CPC分类号： C12Q1/6886 , C12Q2600/106 , C12Q2600/156 , C12Q2600/172
摘要： This invention relates generally to the analytical testing of tissue samples in vitro, and more particularly to aspects of genetic polymorphisms and mutations of the HDAC4 gene. The invention provides new HDAC4 mutations and SNPs, useful in the diagnosis and treatment of subjects in need thereof. Accordingly, the various aspects of the present invention relate to polynucleotides encoding the HDAC4 mutations of the invention, expression vectors encoding the HDAC4 mutant polypeptides of the invention and organisms that express the HDAC4 mutant and polymorphic polynucleotides and/or HDAC4 mutant/polymorphic polypeptides of the invention. The various aspects of the present invention further relate to diagnostic/theranostic methods and kits that use the HDAC4 mutations and polymorphisms of the invention to identify individuals predisposed to disease or to classify individuals with regard to drug responsiveness, side effects, or optimal drug dose.
摘要翻译：本发明一般涉及体外组织样品的分析测试，更具体地涉及HDAC4基因的遗传多态性和突变的方面。本发明提供了可用于诊断和治疗有需要的受试者的新的HDAC4突变和SNP。因此，本发明的各个方面涉及编码本发明的HDAC4突变的多核苷酸，编码本发明的HDAC4突变体多肽的表达载体和表达HDAC4突变体的生物和表达HDAC4突变体的多态性多态性和/或HDAC4突变体/多态性多肽发明。本发明的各个方面进一步涉及使用本发明的HDAC4突变和多态性的诊断/治疗方法和试剂盒来识别易患疾病的个体或者关于药物反应性，副作用或最佳药物剂量对个体进行分类。

78. 发明申请

WO2007009773A1 PYRAZOLO[1.5-A]PYRIMIDIN-7-YL AMINE DERIVATIVES AS PROTEIN KINASE INHIBITORS 审中-公开
标题翻译：作为蛋白激酶抑制剂的吡唑并[1,5-A]吡啶基-7-YL氨衍生物
公开(公告)号：WO2007009773A1
公开(公告)日：2007-01-25
申请号：PCT/EP2006/007109
申请日：2006-07-19
申请人： NOVARTIS AG , NOVARTIS PHARMA GMBH , IMBACH, Patricia , FURET, Pascal , MARTINY-BARON, Georg
发明人： IMBACH, Patricia , FURET, Pascal , MARTINY-BARON, Georg
IPC分类号： C07D487/04 , A61K31/519 , A61P35/00
CPC分类号： C07D487/04
摘要： The invention relates to pyrazolo[1,5a]pyrimidin-7-yl amine derivatives of formula (I) and salts thereof, their use in the treatment of protein kinase dependent diseases.
摘要翻译：本发明涉及式（I）的吡唑并[1,5a]嘧啶-7-基胺衍生物及其盐，它们用于治疗蛋白激酶依赖性疾病。

79. 发明申请

WO2007009715A1 2-CYANO-PYRIMIDINES AND -TRIAZINES AS CYSTEINE PROTEASE INHIBITORS 审中-公开
标题翻译：作为CYSTEINE PROTEASE INHIBITORS的2-氰基 - 吡啶并 - 吡啶
公开(公告)号：WO2007009715A1
公开(公告)日：2007-01-25
申请号：PCT/EP2006/006999
申请日：2006-07-17
申请人： NOVARTIS AG , NOVARTIS PHARMA GMBH , FLOHR, Stefanie , FURET, Pascal , IMBACH, Patricia , HOMMEL, Ulrich , LITSCHER, Hans-Ulrich , GIL PARRADO, Shirley , HASSIEPEN, Ulrich , ZIMMERMANN, Johann
发明人： FLOHR, Stefanie , FURET, Pascal , IMBACH, Patricia , HOMMEL, Ulrich , LITSCHER, Hans-Ulrich , GIL PARRADO, Shirley , HASSIEPEN, Ulrich , ZIMMERMANN, Johann
IPC分类号： C07D239/42 , C07D239/34 , A61K31/505 , A61P19/10
CPC分类号： C07D239/34 , C07D239/42
摘要： The invention relates to compounds of the formula (I) and salts thereof, to a process for their manufacture, to their use in the treatment of (especially cysteine protease, such as UCH-L3- and/or USP-2 dependent) diseases or for the manufacture of pharmaceutical formulations against these diseases, methods of treatment of warm-blooded animals comprising administering the compounds and/or their salts to said animals and pharmaceutical preparations, especially for the treatment of the diseases, comprising said compounds and/or salts.
摘要翻译：本发明涉及式（I）化合物及其盐，其制备方法，用于治疗（特别是半胱氨酸蛋白酶，如UCH-L3-和/或USP-2依赖性）疾病或用于制备针对这些疾病的药物制剂，治疗温血动物的方法包括向所述动物和药物制剂施用化合物和/或其盐，特别是用于治疗包含所述化合物和/或盐的疾病。

80. 发明申请

WO2006050945A3 TUBULIN MUTATION DIAGNOSTIC 审中-公开
标题翻译： TUBULIN MUTATION诊断
公开(公告)号：WO2006050945A3
公开(公告)日：2007-01-25
申请号：PCT/EP2005012044
申请日：2005-11-10
申请人： NOVARTIS AG , NOVARTIS PHARMA GMBH , CULVER KENNETH WAYNE , WARTMANN MARKUS , LILLEBERG STAN , ZHU JIAN
发明人： CULVER KENNETH WAYNE , WARTMANN MARKUS , LILLEBERG STAN , ZHU JIAN
IPC分类号： C12Q1/68 , C07K14/47 , G01N33/50 , G01N33/68
CPC分类号： C12Q1/6883 , C07K14/47 , C12Q2600/106 , C12Q2600/156 , G01N33/5008 , G01N33/5011 , G01N33/68 , G01N33/6848 , G01N2800/52
摘要： The present invention relates to methods for determining the potential of a subject to respond to a particular therapeutic agent, by determining the presence of one or more nucleotide or amino acid variants in the ß-tubulin gene or protein. Also provided are methods for treating subjects whose potential to respond to a therapeutic agent has been evaluated. For use in the methods of the invention, there are provided variants of the ß-tubulin gene, variants of the ß-tubulin protein, nucleic acid molecules and agents which bind to the variant ß-tubulin nucleic acid molecules and variant ß-tubulin protein, respectively, and kits comprising the same.
摘要翻译：本发明涉及通过测定β-微管蛋白基因或蛋白质中一个或多个核苷酸或氨基酸变体的存在来确定受试者对特定治疗剂的响应潜力的方法。还提供了用于治疗对治疗剂有响应的潜能的方法。为了用于本发明的方法，提供β-微管蛋白基因的变体，β-微管蛋白的变体，结合变体β-微管蛋白核酸分子和变体β-微管蛋白的核酸分子和试剂，以及包含其的试剂盒。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式